Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CCR1 | P32246 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23083184 | 0.85 | PDE10A (0.49) | KDM4ELMNAMEN1KMT2ACCR1 | |
| SCHEMBL276117 | 0.82 | SUCNR1 (0.50) | KDM4ELMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL4823229 | 0.82 | ALDH1A1 (0.48) | KDM4ELMNAMEN1KMT2ACCR1 | |
| SCHEMBL20517681 | 0.80 | SUCNR1 (0.49) | KDM4ELMNAMEN1KMT2APDE10A | |
| SCHEMBL2009161 | 0.80 | CCR1 (0.48) | KDM4ELMNAMEN1KMT2ACCR1 | |
| SCHEMBL7514147 | 0.80 | ALDH1A1 (0.47) | KDM4ELMNAMEN1KMT2ACCR1 | |
| SCHEMBL19952703 | 0.80 | ALDH1A1 (0.47) | KDM4ELMNAMEN1KMT2ACCR1 | |
| Alcohol SCHEMBL16115812 | 0.79 | KDM4E (0.47) | KDM4ELMNAMEN1KMT2ACCR1 | |
| SCHEMBL12895009 | 0.78 | PDE10A (0.49) | KDM4ELMNAMEN1KMT2ACCR1 | |
| SCHEMBL7555954 | 0.78 | CCR1 (0.69) | KDM4ELMNACCR1ALDH1A1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256427-A | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-110204544-A | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-106795156-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-105646487-B | A kind of 7-naphthyridine derivatives of bromo 1,8 and preparation method thereof | 红河学院 | 2017-12-05 | — | — | CN | disclosed |
| CN-106795156-A | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2017-05-31 | — | — | CN | disclosed |
| US-7825254-B2 | Heteroaromatic quinoline compounds | PFIZER INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1841757-B1 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PROD INC (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7429665-B2 | Heteroaromatic quinoline compounds | PFIZER INC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | disclosed |
| US-7417062-B2 | e.g. N (S)-(1-Cyclohexylmethyl-pyrrolidine-2-ylmethyl)-3,4-dimethoxy-N-naphthalen-2-ylmethyl-benzamide; inhibit the binding of the SDF-1 (CXCL12) chemokine or I-TAC (CXCL11) to the chemokine receptor CCXCKR2; anticarcinogenic agent; breast, lymph nodes, bone marrow, and lungs cancer | CHEMOCENTRYX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417062-B2 | e.g. N (S)-(1-Cyclohexylmethyl-pyrrolidine-2-ylmethyl)-3,4-dimethoxy-N-naphthalen-2-ylmethyl-benzamide; inhibit the binding of the SDF-1 (CXCL12) chemokine or I-TAC (CXCL11) to the chemokine receptor CCXCKR2; anticarcinogenic agent; breast, lymph nodes, bone marrow, and lungs cancer | CHEMOCENTRYX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417062-B2 | e.g. N (S)-(1-Cyclohexylmethyl-pyrrolidine-2-ylmethyl)-3,4-dimethoxy-N-naphthalen-2-ylmethyl-benzamide; inhibit the binding of the SDF-1 (CXCL12) chemokine or I-TAC (CXCL11) to the chemokine receptor CCXCKR2; anticarcinogenic agent; breast, lymph nodes, bone marrow, and lungs cancer | CHEMOCENTRYX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1841757-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Pfizer Products Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PFIZER INC | 2006-07-13 | — | — | US | disclosed |
| WO-2006072828-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006038989-A1 | SUBSTITUTED ARYLAMIDES | CHEMOCENTRYX, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074071-A1 | Substituted arylamides | CHEMOCENTRYX, INC. (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074071-A1 | Substituted arylamides | AADAC, BRDT, BRPF3 | KDM4E 496/4885LMNA 1960/4885MEN1 3131/4885 |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PDE12, PDE7A, PDE4A | KDM4E 1059/4885LMNA 2994/4885MEN1 1937/4885 |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PDE12, PDE7A, PDE4A | KDM4E 1059/4885LMNA 2994/4885MEN1 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.